Abstract
MicroRNAs (miRNAs) are short, noncoding, and single-stranded RNA molecules that negatively regulate gene expression. They are evolutionarily conserved from plants to animals. During the last decade, miRNAs have been demonstrated as regulators in fundamental biological processes, including cell growth, proliferation, differentiation and apoptosis. By base pairing to the complementary sites in the mRNA of the target gene, miRNA can lead to repression of protein translation or cleavage of mRNA. Among over 700 miRNAs identified in the human genome, several of them were confirmed as ‘oncomirs ’, which denote miRNAs associated with initiation and progression of cancers. Generally, depending on their target genes, these miRNAs function as tumor suppressors or oncogenes. However, the miR-17-92 cluster in the human genome, which encodes 7 mature microRNAs, has been validated as regulator showing both oncogenic and tumor suppressive properties. The miR-17-92 cluster targets mRNAs involved in distinct pathways so that it may exert opposing effects. The transcription factors E2Fs and c-Myc, which play critical roles in tumorigenesis, could interact with the cluster. The feedback loops, which are comprised of the transcription factors and the miR-17-92 cluster, weave a complex regulation net work of cancers. The duality of this cluster reflects the complexities of cancer progressions as well as the intricacies of the regulation network of miRNAs and their targets. With the help of the development of new experimental methods and bioinformatics, further researches on the miR-17-92 cluster and other oncomirs will give new insights into cancer diagnosis, therapy, and prognosis.
Keywords: microRNAs (miRNAs), the miR-17-92 cluster, oncomir, cancer, siRNAs, c-Myc, E2Fs
Current Genomics
Title: Feud or Friend? The Role of the miR-17-92 Cluster in Tumorigenesis
Volume: 11 Issue: 2
Author(s): Jie Xiang and Ji Wu
Affiliation:
Keywords: microRNAs (miRNAs), the miR-17-92 cluster, oncomir, cancer, siRNAs, c-Myc, E2Fs
Abstract: MicroRNAs (miRNAs) are short, noncoding, and single-stranded RNA molecules that negatively regulate gene expression. They are evolutionarily conserved from plants to animals. During the last decade, miRNAs have been demonstrated as regulators in fundamental biological processes, including cell growth, proliferation, differentiation and apoptosis. By base pairing to the complementary sites in the mRNA of the target gene, miRNA can lead to repression of protein translation or cleavage of mRNA. Among over 700 miRNAs identified in the human genome, several of them were confirmed as ‘oncomirs ’, which denote miRNAs associated with initiation and progression of cancers. Generally, depending on their target genes, these miRNAs function as tumor suppressors or oncogenes. However, the miR-17-92 cluster in the human genome, which encodes 7 mature microRNAs, has been validated as regulator showing both oncogenic and tumor suppressive properties. The miR-17-92 cluster targets mRNAs involved in distinct pathways so that it may exert opposing effects. The transcription factors E2Fs and c-Myc, which play critical roles in tumorigenesis, could interact with the cluster. The feedback loops, which are comprised of the transcription factors and the miR-17-92 cluster, weave a complex regulation net work of cancers. The duality of this cluster reflects the complexities of cancer progressions as well as the intricacies of the regulation network of miRNAs and their targets. With the help of the development of new experimental methods and bioinformatics, further researches on the miR-17-92 cluster and other oncomirs will give new insights into cancer diagnosis, therapy, and prognosis.
Export Options
About this article
Cite this article as:
Xiang Jie and Wu Ji, Feud or Friend? The Role of the miR-17-92 Cluster in Tumorigenesis, Current Genomics 2010; 11 (2) . https://dx.doi.org/10.2174/138920210790886853
DOI https://dx.doi.org/10.2174/138920210790886853 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tyrosine Kinase Inhibitors
Current Cancer Drug Targets The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases
Current Cancer Drug Targets Role of Vitamins in Human Health and Nutrition: Sources and Morbidity
Current Nutrition & Food Science Decreased lncRNA SNHG16 Accelerates Oxidative Stress Induced Pathological Angiogenesis in Human Retinal Microvascular Endothelial Cells by Regulating miR-195/mfn2 Axis
Current Pharmaceutical Design Iontophoresis: Drug Delivery System by Applying an Electrical Potential Across the Skin
Drug Delivery Letters Patent Selections
Recent Patents on Biomarkers Cationic Liposomes as Non-viral Vector for RNA Delivery in Cancer Immunotherapy
Recent Patents on Drug Delivery & Formulation Meal Replacement Beverage Twice a Day in Overweight and Obese Adults (MDRC2012-001)
Current Nutrition & Food Science Curcumin as an Anti-Cancer Agent: Review of the Gap Between Basic and Clinical Applications
Current Medicinal Chemistry Oxygen Sensing, Cardiac Ischemia, HIF-1α and Some Emerging Concepts
Current Cardiology Reviews Hibiscus Sabdariffa Linnaeus (Malvaceae), Curcumin and Resveratrol as Alternative Medicinal Agents Against Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry CCNE1 Promotes Progression and is Associated with Poor Prognosis in Lung Adenocarcinoma
Current Pharmaceutical Biotechnology Role of Natural Phenolic Compounds in Cancer Chemoprevention via Regulation of the Cell Cycle
Current Pharmaceutical Biotechnology Biochemistry and Biology of 2'-Fluoro-2'-Deoxythymidine (FT), A Putative Highly Selective Substrate for Thymidine Kinase Type 2 (TK2)
Current Radiopharmaceuticals Epigenetic Mechanism Involved in the HBV/HCV-Related Hepatocellular Carcinoma Tumorigenesis
Current Pharmaceutical Design Key Questions in Metastasis: New Insights in Molecular Pathways and Therapeutic Implications
Current Pharmaceutical Biotechnology Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer
Current Medicinal Chemistry Antisynthetase Syndrome: A Review of Etiopathogenesis, Diagnosis and Management
Current Medicinal Chemistry Teratogenic Toxicity Evaluation of Bladder Cancer-Specific Oncolytic Adenovirus on Mice
Current Gene Therapy Prognostic Implications of Immunohistochemical Biomarkers in Non-muscle-invasive Blad Cancer and Muscle-invasive Bladder Cancer
Mini-Reviews in Medicinal Chemistry